Efficacy of Retreatments With Intravitreal Bevacizumab

Asociación para Evitar la Ceguera en México

Status and phase: Terminated; Phase 3

Conditions: Choroidal Neovascularization; Age Related Macular Degeneration

Treatments: Drug: Intravitreal injection of Bevacizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT00406744

APEC-0012

Details and patient eligibility

About

Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated efficacy of bevacizumab in several pathologies but we dont know what would be the results if we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab for improve or stabilize visual acuity with two or more intravitreal inyections of bevacizumab.

Enrollment: 20 patients

Sex: All

Ages: 60 to 95 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• * Any visual acuity

  • OCT: Central foveal thickness greater than 300 u or with evidence of subretinal fluid.
  • Active angiogram leakage

Exclusion criteria

• * Basal Inflammatory disease

  • Endoftalmitis history
  • Lesions bigger than 5400 u or with scarring greater than 50% of lesion.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)